Physician profile
Gina E Pearson
NPI 1790069722
$2,606.31
in general payments reported to CMS, 2019-2025
34 companies · $45.74 in 2025
The $45.74 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,432 · 2022: $876 · 2023: $174 · 2024: $78.10 · 2025: $45.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $168 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $168.32 |
| Education | $129.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $295.17 | 2021-2022 | |
| Janssen Biotech, INC. | $269.03 | 2021-2023 | Darzalex |
| Novartis Pharmaceuticals Corporation | $252.95 | 2021-2022 | |
| Abbvie INC. | $237.50 | 2021-2024 | |
| Amgen INC. | $230.28 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $158.03 | 2021 | |
| Genzyme Corporation | $116.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $92.68 | 2021-2023 | Lynparza, Keytruda |
| Boston Scientific Corporation | $85.04 | 2024-2025 | General - Pain Management |
| Astellas Pharma US INC | $84.94 | 2021 | |
| Puma Biotechnology, INC. | $81.88 | 2021-2022 | |
| Aveo Pharmaceuticals, INC. | $77.83 | 2022-2023 | Fotivda |
| Incyte Corporation | $71.93 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $62.75 | 2021-2022 | |
| Lilly USA, LLC | $60.88 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $44.89 | 2021-2022 | |
| Taiho Oncology, INC. | $39.86 | 2021-2022 | |
| Genentech USA, INC. | $34.63 | 2022 | |
| Celgene Corporation | $32.70 | 2021-2022 | |
| Deciphera Pharmaceuticals INC. | $31.29 | 2021-2022 | |
| Acrotech Biopharma INC. | $26.25 | 2021 | |
| Pharmaessentia USA Corporation | $22.33 | 2022 | |
| Eisai INC. | $22.26 | 2021 | |
| Epizyme, INC. | $20.14 | 2021 | |
| Pfizer INC. | $19.86 | 2022 | |
| Clovis Oncology, INC. | $18.59 | 2022 | |
| Gilead Sciences, INC. | $17.59 | 2021 | |
| G1 Therapeutics, INC. | $16.62 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $15.21 | 2023 | Imbruvica |
| Glaxosmithkline, LLC. | $15.10 | 2021 | |
| Exelixis INC. | $14.30 | 2021 | |
| Karyopharm Therapeutics INC. | $13.53 | 2022 | |
| Myriad Genetic Laboratories, INC. | $12.20 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.